Clinical trials: in Finland
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
The BIOMEDE 2.0 study is the second stage of the BIOMEDE multi-arm, multistage rolling programme (adaptive platform protocol). It is a multicenter, randomized, open-label, controlled phase-3 trial evaluating efficacy of ONC201 in…
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered
- Trial name
- BIOMEDE 2 (NCT05476939)
- Testing
- Everolimus, ONC201, Radiotherapy
- Where
- 56 sites in Belgium, Denmark and 6 more
- Volunteers
- 433 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Chronic Rhinosinusitis With Nasal Polyps
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
EFC18418 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study with 3 treatment groups.
- Trial name
- CEREN-1 (NCT06834347)
- Testing
- Itepekimab (SAR440340), Mometasone furoate nasal spray (MFNS)
- Where
- 121 sites in United States, Argentina and 19 more
- Volunteers
- 231 people
- Sponsor
- Sanofi
Prostatic Neoplasms, Castration-Resistant
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01).
- Trial name
- NCT06353386
- Testing
- Opevesostat, Olaparib, Docetaxel
- Where
- 77 sites in United States, Australia and 18 more
- Volunteers
- 220 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension
Effectiveness and Cost-Effectiveness of a Digital Care Pathway and Asynchronous Communication for Patients With Hypertension
The goal of this clinical trial is to learn if digital care pathway (DCP) and digital non-real-time messaging, in other words, asynchronous communication (AC) with nurse works to treat high blood pressure in adults in primary…
- Trial name
- DEPTH (NCT07812350)
- Testing
- Digital care pathway for hypertension, Asynchronous communication with nurse
- Where
- 6 sites in Finland
- Volunteers
- 600 people
- Sponsor
- Wellbeing Services County of Pirkanmaa
Hepatocellular Carcinoma
A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer
In this study, researchers want to learn about the safety of a new drug, BAY 3547926, and how well the drug works in people with a type of liver cancer called advanced hepatocellular carcinoma (HCC), which has a special protein…
- Trial name
- BANTAM-01 (NCT06764316)
- Testing
- BAY 3547926, BAY 3547922, BAY 3713391
- Where
- 36 sites in United States, Belgium and 7 more
- Volunteers
- 148 people
- Sponsor
- Bayer
Higher Risk Myelodysplastic Syndromes
Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes
This Phase IIb study (BEXERA) will evaluate the safety and efficacy of bexmarilimab (FP-1305), an antibody targeting Clever-1, given in combination with azacitidine compared with azacitidine plus placebo in adults with…
- Trial name
- BEXERA (NCT07672769)
- Testing
- bexmarilimab (1mg/kg), azacitidine, bexmarilimab (3mg/kg)
- Where
- 35 sites in United States, Czechia and 5 more
- Volunteers
- 90 people
- Sponsor
- Faron Pharmaceuticals Ltd
Celiac Disease, Celiac Disease in Children
Celiac Disease in Childhood-Adulthood Transition
Aims of this study are to evaluate adolescents with celiac disease during their transition from pediatrics to adult care, and to develop better healthcare follow-up practices.
- Conditions
- Celiac Disease, Celiac Disease in Children, Transition of Care, Follow-up
- Trial name
- CeliCAT (NCT05084937)
- Testing
- CeliCAT form
- Where
- 5 sites in Finland
- Volunteers
- 400 people
- Sponsor
- Tampere University Hospital
Renal Cell Carcinoma
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo.
- Trial name
- COSMIC-313 (NCT03937219)
- Testing
- Cabozantinib, Nivolumab, Ipilimumab
- Where
- 159 sites in United States, Argentina and 23 more
- Volunteers
- 855 people
- Sponsor
- Exelixis
Acute Myocardial Infarction, Coronary Artery Disease
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
COMPLETE-2 is a prospective, multi-centre, randomized controlled trial comparing a strategy of physiology-guided complete revascularization to angiography-guided complete revascularization in patients with acute ST-segment…
- Trial name
- COMPLETE-2 (NCT05701358)
- Testing
- Physiology-guided NCL PCI, Angiography-guided NCL PCI
- Where
- 138 sites in United States, Australia and 18 more
- Volunteers
- 5,100 people
- Sponsor
- Population Health Research Institute
Dental Caries, Teeth Loss
The Effect of Bitewing Radiography on Outcomes and Costs of Treating Caries in Permanent Teeth
Dentists commonly use bitewing radiographs (dental X-rays) together with a visual-tactile (clinical) examination to detect cavities between the back teeth.
- Conditions
- Dental Caries, Teeth Loss, Necrosis of Pulp, Irreversible Pulpitis
- Trial name
- BROCC (NCT07882693)
- Testing
- Visual-tactile caries examination, Visual-tactile caries examination and bilateral bitewing radiography
- Where
- Finland
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Jukka Leinonen
Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
Current therapeutic strategies for high-risk or relapsed ALL patients often involve intensive treatments, including allogeneic hematopoietic stem cell transplantation (HSCT).
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant, Graft -Versus-host-disease
- Trial name
- FORUM2 (NCT07297914)
- Testing
- Total Body Irradiation 8 Gy, Ruxolitinib, Blinatumomab
- Where
- 9 sites in Austria, Czechia and 7 more
- Volunteers
- 1,000 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Neoplasms, Lung
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread.
- Trial name
- NCT07099898
- Testing
- Risvutatug rezetecan (Ris-Rez), Topotecan
- Where
- 144 sites in United States, Argentina and 23 more
- Volunteers
- 420 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Renal Cell
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded…
- Trial name
- NCT04195750
- Testing
- Belzutifan, Everolimus
- Where
- 172 sites in United States, Brazil and 21 more
- Volunteers
- 755 people
- Sponsor
- Merck Sharp & Dohme LLC
Coronavirus Disease (COVID-19)
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most often causes mild flu or cold-like symptoms.
- Trial name
- MOVe-NOW (NCT06667700)
- Testing
- Molnupiravir
- Where
- 227 sites in United States, Argentina and 22 more
- Volunteers
- 3,082 people
- Sponsor
- Merck Sharp & Dohme LLC
Pancreatic Surgery, Prophylactic SBRT
Stereotactic Body Radiotherapy (SBRT) Induced Pancreatic Atrophy for Prevention of Post Operative Pancreatic Fistulae (POPF) After Pancreatoduodenectomy in Very High-Risk Patients (STEREOPANC)
STEREOPANC is a randomized, controlled, open label, multicenter study initiated by the Oulu HPB Study Group. Patients with a very high risk of B/C POPF (soft pancreas) scheduled for PD for any indication are recognized at a local…
- Conditions
- Pancreatic Surgery, Prophylactic SBRT, Pancreatic Leak
- Trial name
- STEREOPANC (NCT07884019)
- Testing
- Remnant pancreas SBRT
- Where
- 3 sites in Finland
- Volunteers
- 70 people
- Sponsor
- Oulu University Hospital
Cardiac Rhythm Disorders, Urological Disorders
Product Surveillance Registry
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products.
- Conditions
- Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders
- Trial name
- PSR (NCT01524276)
- Where
- 402 sites in United States, Argentina and 39 more
- Volunteers
- 100,000 people
- Sponsor
- Medtronic
Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves…
- Trial name
- NCT07472517
- Testing
- obrixtamig, atezolizumab, carboplatin
- Where
- 245 sites in United States, Argentina and 40 more
- Volunteers
- 670 people
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes Mellitus With Diabetic Nephropathy
dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
The aim of this study is to test the hypothesis that dapagliflozin (SGLT2 inhibitor) and SC0062 (ERA) combination therapy augments nephroprotection and mitigates fluid retention and ketogenesis in people with T1D through…
- Trial name
- ASPIRE-1 (NCT06072326)
- Testing
- Dapagliflozin (Forxiga®), SC0062 strength 10mg, SC0062 and dapagliflozin
- Where
- 5 sites in Denmark, Finland
- Volunteers
- 36 people
- Sponsor
- University Medical Center Groningen
Ovarian Cancer
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
The objective of this study was to evaluate the efficacy and safety of alpelisib in combination with olaparib compared with single-agent cytotoxic chemotherapy in participants with platinum-resistant or platinum-refractory…
- Trial name
- NCT04729387
- Testing
- Alpelisib, Olaparib, Paclitaxel
- Where
- 93 sites in United States, Argentina and 24 more
- Volunteers
- 358 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.
- Trial name
- NCT07062965
- Testing
- PF-07248144, Fulvestrant, Everolimus
- Where
- 433 sites in United States, Argentina and 29 more
- Volunteers
- 400 people
- Sponsor
- Pfizer